Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin holds near $77K as investors await Fed decision, eyeing $76K support and $83K resistance levels.

Market News
14 Sep 2026
Crypto news
View Source
Neutral
Bitcoin holds near $77K as investors await Fed decision, eyeing $76K support and $83K resistance levels.

Bitcoin is trading near $77,000 as investors adopt a cautious stance ahead of the Federal Reserve's policy decision on September 16, with markets pricing in an 86%–87% chance of a 25-basis-point rate hike. Analysts highlight $76,000 as key support and $83,000 as resistance levels that need strong volume to confirm Bitcoin's next directional move. U.S. spot Bitcoin ETFs saw about $463 million in net outflows last week, indicating weakened but not vanished demand. Additional risks include potential tightening from a Bank of Japan rate hike and the U.S. Senate's pending vote on the CLARITY Act, which could affect crypto market regulation. Investors are waiting for clearer central bank guidance before making significant moves.

Bitcoin analysts' warnings on Fed and BoJ decisions come as a backdrop to Pluang's cryptocurrency market data. For readers following crypto, here is Pluang's market snapshot as of Sep 15, 2026 03:26 WIB: out of 50 major cryptocurrencies priced on Pluang, 33 rose and 16 fell today. Notable moves include SXP (Solar) down 46.27% at Rp37 with a typical hold time of 94 days, BAL (Balancer) up 11.14% at Rp16,297 with 85 days typical hold time, and XRP (Ripple) up 9.67% at Rp26,191 with a typical hold time of 71 days and Pluang order activity showing 34% sell and 66% buy.

More News

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech's phase II trial shows 61.3% 12-month survival in refractory metastatic colorectal cancer with vilamakitug.

XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...

Company Fundamentals
Bullish
1 hour ago
Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

Phase II study shows Vilamakitug improves 12-month survival in refractory metastatic colorectal cancer.

XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...

Market News
Bullish
1 hour ago
Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals to acquire 4,300 net royalty acres in North Dakota's Williston Basin

Dorchester Minerals, L.P. has agreed to acquire mineral and royalty interests covering about 4,300 net royalty acres in three counties within North Dakota's Williston Basin. The deal involves a non-taxable contribution and exchange agreement with an ...

Company Fundamentals
Bullish
2 hours ago
Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

Hershey Trust sells shares ahead of Q3 earnings, retaining control amid price hikes and volume drop.

The Hershey Trust Company sold 1,512 common shares under a trading plan but kept voting control through Class B shares. Hershey will report Q3 earnings on October 29, with investors focused on how price increases affected Halloween-season demand. Q2 ...

Market News
Neutral
3 hours ago
W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley Q3 2026 earnings beat EPS estimates but revenue dips, net income down 13%.

W. R. Berkley reported mixed Q3 2026 results with earnings per share of $1.17 beating estimates, but revenue fell short at $3.74 billion versus $3.82 billion expected. The company saw premium growth with gross premiums up 3% and net premiums up 1%, s...

Company Fundamentals
Neutral
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App